May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Comparison of Photodynamic Therapy With Verteporfin Combined With Posterior Juxtascleral Triamcinolone Acetonide and Photodynamic Therapy Alone for Age-Related Macular Degeneration
Author Affiliations & Notes
  • D. Tsuchiya
    Ophthalmology, Yamagata Univ Faculty of Medicine, Yamagata, Japan
  • T. Yamamoto
    Ophthalmology, Yamagata Univ Faculty of Medicine, Yamagata, Japan
  • K. Saito
    Ophthalmology, Yamagata Univ Faculty of Medicine, Yamagata, Japan
  • H. Yamashita
    Ophthalmology, Yamagata Univ Faculty of Medicine, Yamagata, Japan
  • Footnotes
    Commercial Relationships  D. Tsuchiya, None; T. Yamamoto, None; K. Saito, None; H. Yamashita, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 270. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. Tsuchiya, T. Yamamoto, K. Saito, H. Yamashita; Comparison of Photodynamic Therapy With Verteporfin Combined With Posterior Juxtascleral Triamcinolone Acetonide and Photodynamic Therapy Alone for Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):270.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To examine the therapeutic effects of posterior juxtascleral triamcinolone acetonide (TA) injection before photodynamic therapy (PDT) versus PDT alone for subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Methods: : Group 1: 71 eyes from 69 patients with exudative AMD treated with PDT alone were included. The mean age was 73.0 years (range: 50 to 90 years).Group 2: 22 eyes from 22 patients with exudative AMD treated with PDT and 20mg of posterior juxtascleral triamcinolone acetonide were included. The mean age was 77.0 years (range: 68 to 83 years). Patients with CNV had been treated with the therapeutic effects of PDT were assessed by flourescein angiography, indocyanine green angiography, optical coherence tomography, and corrected visual acuity. The follow-up period was 12 months.

Results: : All eyes maintained baseline visual acuity in both groups. In group 1, visual acuity was improved by 3 lines or over in 27 eyes (38%), did not change in 31 eyes (44%), decreased by 3 lines decrease or below in 13 eyes (18%). In group 2, visual acuity was improved by 3 lines or over in 5 eyes (23%), did not change in 13 eyes (59%), decreased by 3 lines decrease or below in 4 eyes (18%). The CNV occluded in 56 eyes (79%) of group1, 20 eyes (91%) of group 2. The mean number of treatments was 1.9 in group 1, 1.5 in group 2 (P<0.05 Mann-Whitney U test). The intraocular pressure rises could not be observed post treatment. No systemic complications were observed.

Conclusions: : Combined PDT with posterior juxtascleral TA is effective for stabilization of visual acuity, and may be superior to PDT alone in patients with AMD.

Keywords: age-related macular degeneration • photodynamic therapy • corticosteroids 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×